Kepler Capital Sticks to Its Hold Rating for Novonesis (0Q4U)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2024
0mins
Source: Business Insider
Analyst Ratings: Patrick Roquas from Kepler Capital maintains a Hold rating on Novonesis with a price target of DKK450.00, while UBS also holds a similar stance with a target of DKK430.00, indicating a Moderate Buy consensus among analysts.
Company Overview: Novozymes, the parent company of Novonesis, is a leader in industrial enzymes and has diversified into micro-organisms for agricultural markets, focusing on improving efficiency and sustainability across various industries.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
